Everyone knows semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) cause massive weight loss. But here's what's more interesting: they're both preventing heart attacks, strokes, and deaths. even in people without diabetes. The question nobody could answer until now: which one is actually better for your heart?
Turns out the answer is complicated. And kind of depends on who you are.
The New Data That Changed Everything
Three major studies published between late 2025 and early 2026 tried to compare these drugs head-to-head for cardiovascular outcomes. The results don't all agree.
Mass General Brigham (1 million patients with type 2 diabetes, November 2025):
- Semaglutide reduced heart attack/stroke risk by 18% vs. sitagliptin (a neutral diabetes drug)
- Tirzepatide reduced heart attack/stroke/death risk by 13% vs. dulaglutide (another GLP-1)
- Direct comparison: They're basically tied. Hazard ratio of 1.06 means almost no difference.
Cleveland Clinic (31,000 patients with fatty liver, obesity, and diabetes):
- Tirzepatide linked to lower risks across the board: heart attacks, heart failure hospitalizations, death
- Semaglutide still protective, but tirzepatide came out ahead in this specific population
STEER study (overweight patients with existing heart disease, no diabetes):
- Semaglutide reduced cardiovascular events by 29% compared to tirzepatide in the intent-to-treat analysis
- In people who actually stayed on the drugs (per-protocol): semaglutide's advantage jumped to 57%. including 62% lower heart attack risk and 66% lower heart failure hospitalizations
So which is it? Are they the same? Is tirzepatide better? Is semaglutide better?
Why The Studies Disagree
The populations are completely different.
Tirzepatide looks better in:
- People with type 2 diabetes
- People with fatty liver disease (MASLD)
- Patients who need major metabolic improvements (weight loss, blood sugar, cholesterol all at once)
Semaglutide looks better in:
- People with existing heart disease but no diabetes
- Patients focused primarily on cardiovascular protection rather than weight loss
- People who stay on the medication consistently
The key: These drugs probably work through slightly different mechanisms. Tirzepatide is a dual agonist (hits both GLP-1 and GIP receptors), so it drives bigger metabolic changes. more weight loss, better blood sugar control. That translates to bigger cardiovascular benefits when metabolic disease is the main driver.
Semaglutide has stronger direct effects on the heart and blood vessels. things like endothelial function (how well your blood vessels work). That matters more when you already have heart disease.
What Actually Happens in Your Body
Both drugs reduce cardiovascular risk through multiple pathways:
1. Weight loss. Less stress on your heart, better cholesterol, lower inflammation 2. Blood sugar control. Reduces damage to blood vessels over time 3. Direct heart effects. Better endothelial function, reduced inflammation in vessel walls 4. Blood pressure reduction. Both drugs lower BP slightly
Tirzepatide causes more weight loss (average 22.5% body weight vs. 15% for semaglutide at top doses), so its cardiovascular benefits are partly explained by better metabolic improvements.
Semaglutide's cardiovascular protection appears sooner and persists even with modest weight loss. suggesting stronger direct vascular effects.
The Numbers That Matter
| Study | Population | Tirzepatide Benefit | Semaglutide Benefit | |-------|------------|---------------------|---------------------| | Mass General | T2D, high CV risk | 13% reduction vs. dulaglutide | 18% reduction vs. sitagliptin | | Cleveland Clinic | MASLD + obesity + diabetes | Lower MACE, heart failure, death | Not directly compared | | STEER | Overweight + heart disease, no diabetes | Baseline | 29-57% lower cardiovascular events | | Post-hoc analysis | T2D patients, 72 weeks | ~24% reduction in 10-year CV risk | ~14% reduction in 10-year CV risk |
What This Means For You
If you have type 2 diabetes or fatty liver disease and need to lose a lot of weight: Tirzepatide will probably give you the biggest overall cardiovascular benefit because it tackles all your metabolic problems at once.
If you have existing heart disease but not diabetes: Semaglutide appears to offer better cardiovascular protection in real-world data, especially if you can stay on it consistently.
If you're obese and want heart protection but don't have diabetes or existing heart disease: The data is mixed. Both work. Choose based on side effects, cost, and how much weight loss you need.
The Catches
These aren't perfect comparisons: Different studies used different baseline drugs as comparisons (dulaglutide, sitagliptin, etc.). Intent-to-treat vs. per-protocol analyses give different results.
Adherence matters: The STEER study showed semaglutide's benefits were way bigger in people who actually stayed on it. Both drugs have high discontinuation rates due to GI side effects.
Cost: Both are expensive ($1,000+/month without insurance). If you can't stay on them long-term, the benefits disappear when you stop.
The Takeaways
- Both drugs prevent heart attacks, strokes, and deaths. this is real, consistent across multiple studies
- Tirzepatide wins in metabolic disease (diabetes, fatty liver) where its bigger weight loss and metabolic effects drive more cardiovascular benefit
- Semaglutide wins in existing heart disease without diabetes. stronger direct vascular protection
- The "best" choice depends on your specific situation. not a one-size-fits-all answer
- Staying on the drug matters more than which one you pick. discontinuation kills the benefits
This is educational content, not medical advice. Discuss cardiovascular risk and medication options with your cardiologist.